The strong Q2 beat and reiterated guidance support the stock, but the pipeline catalysts (BP-205 MAD data Q4 2026, Pitolisant GR PDUFA April 2027) are the key upside drivers. Monitor the October 22, 2026 ANDA litigation closing arguments for potential IP risk.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Aug 4 $38.78entry
- T+1 · 3mo ago −1.39%α −1.19% · $38.24
- T+5 · 3mo ago +1.91%α +2.01% · $39.52
- T+20 · due 3mo ago Pending
- T+60 · due 20d ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY and above $253.3M consensus, with diluted EPS of $1.28 beating the $1.15 estimate by 11.5%. The company reiterated full-year WAKIX guidance of $1.0B-$1.04B and disclosed encouraging Phase 1 SAD data for orexin-2 agonist BP-205, supporting a best-in-class profile.
Key Financial Metrics
Key Facts
- Q2 2026 WAKIX net revenue $261.3M, +30% YoY vs $200.5M in Q2 2025
- Diluted EPS $1.28 vs consensus $1.15, an 11.5% beat
- Estimated average patients grew 450 to 8,950 in Q2
- Reiterated 2026 WAKIX net revenue guidance of $1.0B-$1.04B
- Phase 1 SAD data for BP-205 showed favorable PK and safety/tolerability profiles; MAD data expected Q4 2026
- Cash, cash equivalents and investments of $962.5M as of June 30, 2026
- Pitolisant GR NDA accepted with PDUFA date April 1, 2027
- Net income $75.4M vs $39.8M in Q2 2025, +89.5%
Financial Impact
Q2 revenue beat consensus by ~$8M; EPS beat by $0.13; net income doubled YoY to $75.4M
Risk Factors
- ANDA litigation with AET Pharma/Sandoz; closing arguments scheduled October 22, 2026
- Cost of product sold rose to 24.2% of revenue from 19.0% due to new Novitium royalties
- Pipeline assets (BP-205, EPX-100) are early-stage with no near-term revenue contribution
- Dependence on single product WAKIX for all current revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3338190 |
Track record
20 reports on HRMY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
- Nov 4, 202612d ago 8-K Bearish 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
- Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
- Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 No price data
- Aug 4, 202614w ago Press Release Bullish 6/10 Viewing Entry $38.78 Now $32.96 −15.01% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers